Paradigm and Bristol Myers Squibb Collaborate to Enhance Clinical Trial Access and Efficiency
核心洞察
Paradigm (搜索) and Bristol Myers Squibb (搜索) are partnering to create a new clinical trial model focused on improving patient access, accelerating trial completion, and easing provider burden.
The collaboration aims to design trial protocols that align with the capabilities of community health providers, who serve diverse patient populations.
Paradigm (搜索)'s software platform will be leveraged to expand clinical research programs at community health organizations, offering clinical trials as a care option to more patients.
Paradigm (搜索) and Bristol Myers Squibb (搜索) (BMS) have announced a collaboration to develop a novel end-to-end clinical trial operating model, with the goal of expanding patient access, accelerating trial timelines, and reducing the administrative burden on healthcare providers. The collaboration will initially focus on oncology (搜索) trials before expanding to other therapeutic areas.
The partnership leverages Paradigm (搜索)'s network of health systems, which serve diverse patient populations and utilize Paradigm's software to streamline clinical trial recruitment and operations. A key objective is to address the current disparity in clinical trial participation, where less than 5% of cancer (搜索) patients enroll in trials, hindering the progress of new treatments and limiting access to potentially beneficial therapies.
Addressing Barriers to Clinical Trial Enrollment
The collaboration seeks to overcome the administrative hurdles that contribute to low clinical trial enrollment. By designing trial protocols that are compatible with the practical constraints of community health provider organizations, Paradigm (搜索) and BMS aim to make clinical research more accessible to a broader range of patients. Paradigm's software platform, already implemented in numerous community health centers, plays a crucial role in expanding clinical research programs and offering trials as a standard care option.
Paradigm's Role in Streamlining Clinical Trials
Paradigm (搜索)'s CEO, Kent Thoelke, emphasized the importance of equitable access to clinical research for all patients. "Working with a leader like Bristol Myers Squibb (搜索) helps scale equitable access for patients today," said Thoelke. "In the process, we aim to help Bristol Myers Squibb speed up recruitment, attract a more diverse patient population, reduce provider burden, and more rapidly complete trials to increase access to potentially helpful therapies in the future."
Paradigm (搜索)'s platform aims to rebuild the clinical research ecosystem by removing barriers to trial participation for both patients and healthcare providers. By creating a seamless infrastructure within healthcare provider organizations, Paradigm seeks to accelerate the delivery of potentially life-saving therapies to patients.